Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.50 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723965 | 0.84 | GSTP1 (0.47) | MTORCYP11B2CYP11B1CYP17A1CYP19A1 | |
| SCHEMBL15730609 | 0.83 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CGTDO2PRKCI | |
| SCHEMBL18854066 | 0.80 | AKT1 (0.36) | PIK3CDPIK3CBPIK3CGTDO2PRKCI | |
| SCHEMBL15638799 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CGTDO2PRKCI | |
| SCHEMBL18854138 | 0.79 | MAPK9 (0.48) | PIK3CDPIK3CBPIK3CGTDO2PRKCI | |
| SCHEMBL15723912 | 0.78 | ALDH1A1 (0.50) | CYP1A2CYP2C19MAPK14CCNCCDK8 | |
| SCHEMBL15723963 | 0.78 | RAB9A (0.62) | PIK3CDPIK3CBPIK3CGABL1PIK3CA | |
| SCHEMBL15723968 | 0.78 | CYP11B2 (0.54) | CYP11B2CYP11B1CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL15723977 | 0.77 | CYP2A6 (0.52) | TDO2CYP11B1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15730179 | 0.77 | ABL1 (0.51) | PIK3CDPIK3CBPIK3CGTDO2PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PIK3CD 1017/4885PIK3CB 1256/4885PIK3CG 1184/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | PIK3CD 1017/4885PIK3CB 1256/4885PIK3CG 1184/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PIK3CD 1017/4885PIK3CB 1256/4885PIK3CG 1184/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PIK3CD 1017/4885PIK3CB 1256/4885PIK3CG 1184/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PIK3CD 1017/4885PIK3CB 1256/4885PIK3CG 1184/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PIK3CD 1017/4885PIK3CB 1256/4885PIK3CG 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.